Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE The original ERSPC risk calculator 3 (RC3) for prostate cancer (PCa) and high-grade PCa (HGPCa) was applied to a development cohort of 3006 previously unscreened Hong Kong Chinese men with initial transrectal biopsies performed from 1997 to 2015, age 50-80 years, PSA 0.4-50 ng ml<sup>-1</sup> and prostate volume 10-150 ml. 27897172

2017

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE We examined whether the DNA-PK activity of peripheral blood lymphocytes (PBLs) was related to biochemical (prostate-specific antigen: PSA) relapse and radiation toxicity in prostate cancer patients who have received radiotherapy. 28399576

2017

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE The polymorphism rs4430796 of the chromosome 17q12 appears to be a biomarker for cancer aggressiveness, increased PSA and tumor volume of PCa. 24627192

2014

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE We identified 6.509 patients with prostate cancer who had received hormonal therapy with a post-hormonal therapy PSA ≥2ng/mL, 363 of whom had non-metastatic, castrate-resistant prostate cancer. 31851457

2020

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. 31090082

2019

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Although, more clinical validations are needed for the stratification of PC risk in ASAP-diagnosed biopsy cores, our current results indicate that the coexistence of T2E fusion positivity with MMP-2 upregulation may help clinicians adjust their biopsy timetable and/or assessment of PC risk in ASAP-diagnosed patients with a PSA level of 4-10 ng/mL. 30294801

2019

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE In tissue samples, SPRY1 expression levels were significantly lower in prostate cancer patients with PSA recurrence after surgical treatment (P = 0.0076) and JAG1 expression levels were significantly higher in Gleason sum (GS) 8-9 disease than in GS 5-6 (P = 0.0121). 24604720

2014

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE The finding indicates the potential limitations of the suicide gene therapy of prostate cancer based on selectivity of PSA promoter. 16043123

2005

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Prostate-specific antigen (PSA; hK3) and, more recently, human glandular kallikrein (hK2) are widely used tumor markers for prostate cancer. 12142373

2002

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Between 1995 and 2001, 206 men with unfavorable-risk PC were randomized to receive radiation therapy alone or in combination with 6 months of androgen deprivation therapy (ADT); 108 men experienced PSA failure and formed the study cohort. 28117382

2017

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level at diagnosis and the Gleason Score (GS) in prostate biopsy. 29523813

2018

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE We therefore studied VDR gene polymorphisms, as detected by Apal and Taql restriction fragments, in multiethnic Brazilian men (165 patients and 200 controls) for association with prostate cancer risk and parameters of disease severity (serum PSA, Gleason score and tumor stage).No statistical correlations were found. 15503828

2005

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE ERG, SLC45A3 and PTEN immunostaining and their association with pathological features and PSA progression-free survival were analyzed in 220 PrCa (PSMAR-Biobank, Barcelona, Spain). 29088771

2017

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE When we evaluated these two tSNPs together based on the risk alleles (that is, rs6434568 C and rs16834898 A), we found that the combined genotypes with four risk alleles were associated with an increased risk of PCa compared with those carrying 0-3 risk alleles (1.53, 1.19-1.97), and this increased risk was more pronounced among subjects of≤70 years (1.80, 1.24-2.62), Gleason score≥7 (1.68, 1.28-2.22) and PSA level≥20 (1.64, 1.24-2.18). 23459097

2013

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Important randomized trials show a clear benefit to androgen deprivation therapy (ADT) in both intermediate-risk prostate cancer and postprostatectomy patients with rising PSA. 29465428

2018

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Implementation of risk-based prostate cancer screening has been proposed as a means to reduce the harms of PSA screening. 29990335

2018

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Since the widespread adoption of PSA testing, about 60-70% of men at risk in the U.S. have had a blood test for prostate cancer. 15322319

2004

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Our findings suggest that CYP1B1 and PSA variants may affect the risk of prostate cancer and tumor aggressiveness. 16172228

2005

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Combined Early and Late [<sup>68</sup>Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. 30105521

2019

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA 'grey zone'. 29248950

2018

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Our results suggest that rs4962416, previously associated only with prostate cancer, is also associated with PSA levels, with 12% increase for each copy of the minor allele C. The study enabled the replication of the effect for the majority of previously reported genetic variants in a set of clinically relevant prostate cancers. 26773531

2016

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE In both groups there was a curative intention to treat localized high-risk prostate cancer (one or more of Gleason score 8-10, PSA 20-50 or stage T3), diagnosed between 1995-2010, follow-up at the end of 2014. 30990112

2020

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Following negative initial findings of biopsy sample analysis, total serum PSA levels and serum PSA kinetics are ineffective indicators of a need for a repeat biopsy; therefore, patients suspected of having prostate cancer might undergo several unnecessary biopsy procedures. 26171803

2015

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. 26030748

2015

Entrez Id: 5627
Gene Symbol: PROS1
PROS1
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.100 GeneticVariation BEFREE ERG overexpression (ERG+ or ERG-) was determined by immunohistochemistry (IHC) in 1039 radical prostatectomy (RP) tumors and association with PSA, D'Amico risk score, histopathology, biochemical recurrence, body mass index and age of PCa cases was analyzed. 23381693

2013